CRISPR and XIST Silencing Achieve Early Lab Breakthroughs for Down Syndrome

Two new studies point to early-stage lab breakthroughs for Down syndrome: one uses CRISPR to cut and remove the extra chromosome 21 in human cells, the other improves XIST-based gene silencing to switch the extra chromosome off. Both remain years from clinical use but mark a significant conceptual leap.